MX2024005194A - Vacuna de norovirus y métodos de su uso. - Google Patents
Vacuna de norovirus y métodos de su uso.Info
- Publication number
- MX2024005194A MX2024005194A MX2024005194A MX2024005194A MX2024005194A MX 2024005194 A MX2024005194 A MX 2024005194A MX 2024005194 A MX2024005194 A MX 2024005194A MX 2024005194 A MX2024005194 A MX 2024005194A MX 2024005194 A MX2024005194 A MX 2024005194A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- norovirus
- norovirus vaccine
- vaccine
- antigens
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/544—Mucosal route to the airways
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6018—Lipids, e.g. in lipopeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/16011—Caliciviridae
- C12N2770/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/16011—Caliciviridae
- C12N2770/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/16011—Caliciviridae
- C12N2770/16071—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163272439P | 2021-10-27 | 2021-10-27 | |
| PCT/US2022/078753 WO2023076977A1 (en) | 2021-10-27 | 2022-10-27 | Norovirus vaccine and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024005194A true MX2024005194A (es) | 2024-07-22 |
Family
ID=86158598
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024005194A MX2024005194A (es) | 2021-10-27 | 2022-10-27 | Vacuna de norovirus y métodos de su uso. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250018021A1 (https=) |
| EP (1) | EP4422681A4 (https=) |
| JP (1) | JP2024540061A (https=) |
| KR (1) | KR20240111822A (https=) |
| CN (1) | CN118450902A (https=) |
| AU (1) | AU2022379626A1 (https=) |
| CA (1) | CA3235832A1 (https=) |
| IL (1) | IL312261A (https=) |
| MX (1) | MX2024005194A (https=) |
| WO (1) | WO2023076977A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4554617A1 (en) * | 2022-07-13 | 2025-05-21 | ModernaTX, Inc. | Norovirus mrna vaccines |
| KR20260008117A (ko) * | 2023-05-08 | 2026-01-15 | 머크 샤프 앤드 돔 엘엘씨 | 노로바이러스 vp1 항원을 코딩하는 폴리뉴클레오티드 및 그의 용도 |
| KR20250123985A (ko) * | 2024-02-08 | 2025-08-19 | (주)한국바이오셀프 | 노로바이러스 GII mRNA를 포함하는 백신 조성물 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2011276328C1 (en) * | 2010-07-06 | 2016-01-21 | Novartis Ag | Norovirus derived immunogenic compositions and methods |
| US20160185826A1 (en) * | 2014-08-07 | 2016-06-30 | Medigen Biotechnology Corp. | Virus-like particle vaccines |
| EP4631970A3 (en) * | 2016-05-04 | 2026-01-07 | CureVac SE | Nucleic acid molecules and uses thereof |
| WO2019104439A1 (en) * | 2017-11-30 | 2019-06-06 | Medicago Inc. | Modified norovirus vp1 proteins and vlps comprising modified norovirus vp1 proteins |
| US20250002539A1 (en) * | 2021-07-26 | 2025-01-02 | The University Of North Carolina At Chapel Hill | Methods and compositions for norovirus chimeric therapeutics |
-
2022
- 2022-10-27 JP JP2024525251A patent/JP2024540061A/ja active Pending
- 2022-10-27 AU AU2022379626A patent/AU2022379626A1/en active Pending
- 2022-10-27 CN CN202280086321.0A patent/CN118450902A/zh active Pending
- 2022-10-27 EP EP22888483.9A patent/EP4422681A4/en active Pending
- 2022-10-27 US US18/705,288 patent/US20250018021A1/en active Pending
- 2022-10-27 IL IL312261A patent/IL312261A/en unknown
- 2022-10-27 MX MX2024005194A patent/MX2024005194A/es unknown
- 2022-10-27 KR KR1020247017131A patent/KR20240111822A/ko active Pending
- 2022-10-27 CA CA3235832A patent/CA3235832A1/en active Pending
- 2022-10-27 WO PCT/US2022/078753 patent/WO2023076977A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024540061A (ja) | 2024-10-31 |
| WO2023076977A1 (en) | 2023-05-04 |
| CN118450902A (zh) | 2024-08-06 |
| IL312261A (en) | 2024-06-01 |
| US20250018021A1 (en) | 2025-01-16 |
| AU2022379626A1 (en) | 2024-05-30 |
| EP4422681A1 (en) | 2024-09-04 |
| KR20240111822A (ko) | 2024-07-17 |
| CA3235832A1 (en) | 2023-05-04 |
| EP4422681A4 (en) | 2025-11-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024005194A (es) | Vacuna de norovirus y métodos de su uso. | |
| MX2020010941A (es) | Moleculas y composiciones novedosas de arn de vsr para vacunacion. | |
| EA201690425A1 (ru) | Композиции, содержащие аттенуированный вирус ньюкаслской болезни, и способы применения для лечения неоплазии | |
| EA201690754A1 (ru) | Применение ингибитора pcsk9 для лечения гиперлипидемии | |
| EA202092668A1 (ru) | Антитела к ил-11 | |
| MX2022015071A (es) | Moleculas de anticuerpo contra el virus bk. | |
| EA201890571A1 (ru) | Способы и композиции для лечения нарушения, ассоциированного с геном пропротеинконвертазы субтилизин/кексинового типа (pcsk9) | |
| CL2017002230A1 (es) | Tratamiento combinado con un agonista de tlr7 y un inhibidor del ensamblaje de la cápsida del vhb. | |
| EA201400565A1 (ru) | Молекулы антител, имеющие специфичность в отношении ох40 человека | |
| MX2010012860A (es) | Metodos para tratar cancer del sistema nervioso central. | |
| CO2022012272A2 (es) | Vacunas contra el coronavirus y métodos de uso | |
| MX2022010357A (es) | Anticuerpos inhibidores de anti-pcsk9 para el tratamiento de pacientes con hiperlipidemia que se someten aferesis de lipoproteina. | |
| MX2021014771A (es) | Tratamiento combinado con un agonista de tlr7 y un inhibidor de montaje de capsida de hbv. | |
| EA201890878A1 (ru) | Способ лечения медуллобластомы с помощью ингибитора ezh2 | |
| BR112022021957A2 (pt) | Imidazopirimidinas como moduladores de il -17 | |
| MD20170025A2 (ro) | Tratamente terapeutice pe bază de anamorelin | |
| JOP20240161A1 (ar) | طرق لعلاج الخاضعين المصابين بالصدفية اللويحية لفروة الرأس | |
| UY40490A (es) | Vacunas de combinación para prevenir y/o tratar múltiples agentes infecciosos | |
| Kim et al. | Four cases of onychomadesis after hand-foot-mouth disease | |
| UY40331A (es) | Vacuna contra el coronavirus | |
| ZA202212179B (en) | Aptamers for use in the treatment of coronaviridae infections | |
| ZA202309185B (en) | Aptamers for use in the treatment of coronaviridae infections | |
| MX2023010340A (es) | Anticuerpos monoclonales neutralizantes de virus bk. | |
| MX369090B (es) | Sultiame para el tratamiento de apnea del sueño. | |
| AR121859A1 (es) | Vacuna contra el coronavirus |